Payment overview · 2025
General Payments
$1,026.10
21 reported records · 14 companies
Healthcare provider profile · identity verified
David Anthony Lipski, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · LOUISVILLE, KY · NPI 1730111725
Verified facts
What the public records show
CMS Open Payments records show David Anthony Lipski, MD received $1,026.10 in general payments during 2025 across 21 reported records.
Endologix LLC accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $546.25 | 53.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $146.55 | 14.3% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $62.19 | 6.1% | 3 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $44.92 | 4.4% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $35.01 | 3.4% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $34.22 | 3.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.60 | 3.3% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $31.45 | 3.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $22.15 | 2.2% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $15.50 | 1.5% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $14.66 | 1.4% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $13.99 | 1.4% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $12.96 | 1.3% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $12.65 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,026.10 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $546.25 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $129.57 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $62.19 | 3 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $33.60 | 1 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $12.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $12.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $12.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 109 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 60 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 38 |
| Cilostazol | Cilostazol | 40 | 14 |
| Xarelto | Rivaroxaban | 14 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,026.10 · 21 records | Endologix LLC | APLIGRAF, ARTIX MT, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, Alto Abdominal Stent Graft System, Bashir Endovascular Catheter, COLLAGENASE SANTYL, Denali Vena Cava Filter, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, Integra, Integra Dermal Regeneration Template, Iodosorb Ointment 40g USA, Kerecis GraftGuide, Kerecis SurgiClose, PREVENA, PRIMATRIX, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, RENASYS TOUCH, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TREO ABDOMINAL STENT-GRAFT SYSTEM, V.A.C. VERAFLO CLEANSE CHOICE, VENASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error